Medicine focus

Aduhelm (aducanumab) is a monthly intravenous infusion intended to slow cognitive decline by reducing amyloid beta plaques in the brain.

Ubrelvy (ubrogepant) is a calcitonin gene-related peptide (CGRP) receptor antagonist indicated for the acute treatment of migraine headaches with or without aura.

Tukysa (tucatinib) is a medication used in combination with trastuzumab and capecitabine for the treatment of adult patients with advanced, unresectable or metastatic HER2-positive breast cancer.

Radicut (edaravone) and Radicava (edaravone) is a medication for the treatment of patients with amyotrophic lateral sclerosis (ALS) and acute ischaemic stroke.

Trodelvy (sacituzumab govitecan-hziy) is an immune targeted therapy used for the 3rd line treatment of patients with metastatic triple-negative breast cancer (mTNBC).

Tagrisso (osimertinib) is a kinase inhibitor (targeted therapy) medication.

Vyndaqel (tafamidis) is a medicine indicated for the treatment of transthyretin amyloidosis in patients with stage 1 symptomatic polyneuropathy to delay peripheral neurologic impairment.

Tibsovo (ivosidenib) is an IDH1 inhibitor (targeted therapy) medication.

Enhertu (fam-trastuzumab deruxtecan-nxki) is an antibody-drug conjugate targeted therapy.

Aimovig (erenumab) is a preventive migraine treatment that works by blocking the activity of calcitonin gene-related peptide, a molecule that is involved in migraine attacks

5 common questions about the supplement that may be useful for ALS, Parkinson's and Alzheimers.